The pneumococcal conjugate vaccine Vaxneuvance (PCV15) has been given a UK license by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in children aged six weeks to less than 18 years, for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae infection. The vaccine, manufactured by MSD, is already indicated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. View More